Abstract Library

#919 Effect of Combined Treatment with mTOR Inhibitors (mTORi) and Dopamine Agonists on Cell Proliferation in a Human Typical Lung Carcinoid Cell Line

Introduction: The mTOR pathway and dopamine receptors are potential targets for treatment of neuroendocrine tumors (NET).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Sarnataro M

Authors: Sarnataro M, Pivonello C, De Martino M, Sciammarella C, Cuomo G,

Keywords: mTOR, dopamine,

#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors

Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sciammarella C, Pivonello C, Sarnataro M, Marotta V, Ramundo V,

Keywords: mTOR pathway, everolimus, pancreatic NET, bronchial carcinoids,

#532 Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line

Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pivonello R, Sarnataro M, Cariati F, Pivonello C, Colao A,

Keywords: neuroendocrine tumor, mTOR inhibitors, dopamine agonists, somatostatin analogues,